This is a working overview of circadian rhythm, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-10-11 and is reviewed periodically as new material appears.
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C or lower | Desiccated and protected from light |
| Common analytical method | LC-MS/MS | Detects parent drug and metabolites |
| Solubility class | Lipophilic; soluble in organic solvents | Low aqueous solubility |
| Molecular weight | 437.94 g/mol | Calculated from reported formula |
| Synonyms | SR9009; REV-ERB agonist | Code name used in scientific literature |
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
=== Bid to return to coaching Essendon === Towards the end of the 2026 AFL season, Hird made a bid to return as coach for Essendon in 2027. However, the board eventually decided to select Mark McVeigh, who played alongside with, and was coached by, Hird at Essendon.
AMPH-B can be toxic after prolonged exposure, making it a good candidate for the targeting and rapid clearing of systemic circulation of LTLs. AmBisome is also effective due to the inflammation in the area of fungal activity, which increases vascular permeation.
Thioesters are prominent active esters, as illustrated by the esters of coenzyme A. Terpenes and terpenoids are generated from active esters. Some biosynthetically significant active esters include isopentenyl pyrophosphate, dimethylallyl pyrophosphate, and geranyl pyrophosphate.
=== Organic chemistry === In organic chemistry, menthol is used as a chiral auxiliary in asymmetric synthesis. For example, sulfinate esters made from sulfenyl chlorides and menthol can be used to make enantiomerically pure sulfoxides by reaction with organolithium reagents or Grignard reagents. Menthol reacts with chiral carboxylic acids to give diastereomic menthyl esters, which are useful for chiral resolution.
=== Gelation === Silica aerogels are typically synthesized by using a sol-gel process. The first step of the sol-gel process is the creation of a colloidal suspension of solid particles known as a "sol". The precursors are a liquid alcohol such as ethanol which is mixed with a silicon alkoxide, such as tetramethoxysilane (TMOS), tetraethoxysilane (TEOS), and polyethoxydisiloxane (PEDS) (earlier work used sodium silicates). The solution of silica is mixed with a catalyst and allowed to gel during a hydrolysis reaction which forms particles of silicon dioxide. The oxide suspension begins to undergo condensation reactions which result in the creation of metal oxide bridges (either M–O–M, "oxo" bridges, or M–OH–M, "ol" bridges) linking the dispersed colloidal particles. These reactions generally have moderately slow reaction rates, and as a result either acidic or basic catalysts are used to improve the processing speed. Basic catalysts tend to produce more transparent aerogels and minimize the shrinkage during the drying process and also strengthen it to prevent pore collapse during drying. For some materials, the transition from a colloidal dispersion into a gel happens without the addition of crosslinking materials. For others, crosslinking materials are added to the dispersion to promote the strong interaction of the solid particles in order to form the gel. The gelation time depends heavily on a variety of factors such as the chemical composition of the precursor solution, the concentration of the precursor materials and additives, the processing temperature, and the pH.
Sources: en.wikipedia.org
The aromatic amino acids phenylalanine, tryptophan, and tyrosine Indole, indole derivatives and tryptophan 2,3-Dihydroxybenzoic acid (DHB) used for enterobactin biosynthesis The plant hormone salicylic acid Many alkaloids and other aromatic metabolites. The folate precursor para-aminobenzoate (pABA) The biosynthesis of vitamin K and folate in plants and microorganisms. The name chorismic acid derives from a classical Greek word χωρίζω meaning "to separate", because the compound plays a role as a branch-point in aromatic amino acid biosynthesis.
=== Human health === Although there are only very few reported cases and epidemiological data, the FDA has set an action limit of 50 ppb in cider due to its potential carcinogenicity and other reported adverse effects. In humans, it was tested as an antiviral intranasally for use against the common cold with few significant adverse effects, yet also had negligible or no beneficial effect.
== Personal life == Hird married Tania Poynton on 11 October 1997. Around the time of the marriage, Poynton was working as a lawyer at legal firm Corrs Chambers Westgarth, where she remained until 2002. The couple have since separated. Hird shares four children with Tania: a daughter and three sons. One of his sons, Thomas Hird, was signed as a category B rookie at Essendon in 2019 and was delisted by Essendon in 2022. Tom Hird now plays for the Port Melbourne Football Club in the Victorian Football League. Hird's paternal grandfather, the late Allan Hird, Sr., was a notable player for and president of the Essendon Football Club, and his father, Allan Hird, Jr., had a brief playing career with Essendon. Hird completed a bachelor's degree in civil engineering in 1998 and worked in that capacity as a consultant on the CityLink project. He has also spent time working for a stockbroking firm and is an active partner in Gemba, a sports marketing and media consultancy firm based in Melbourne. He is the founder and managing director of Euree Asset Management, where he currently works. On 5 January 2017, Hird was taken to a private hospital following a drug overdose and suspected suicide attempt and was subsequently transferred to a specialist mental health care facility for further care and treatment. On 28 November 2018, Hird was hit by a car when cycling in Richmond.
== Drug targets == A biomolecular target (most commonly a protein or a nucleic acid) is a key molecule involved in a particular metabolic or signaling pathway that is associated with a specific disease condition or pathology or to the infectivity or survival of a microbial pathogen. Potential drug targets are not necessarily disease causing but must by definition be disease modifying. In some cases, small molecules will be designed to enhance or inhibit the target function in the specific disease modifying pathway. Small molecules (for example receptor agonists, antagonists, inverse agonists, or modulators; enzyme activators or inhibitors; or ion channel openers or blockers) will be designed that are complementary to the binding site of target. Small molecules (drugs) can be designed so as not to affect any other important "off-target" molecules (often referred to as antitargets) since drug interactions with off-target molecules may lead to undesirable side effects. Due to similarities in binding sites, closely related targets identified through sequence homology have the highest chance of cross reactivity and hence highest side effect potential. Most commonly, drugs are organic small molecules produced through chemical synthesis, but biopolymer-based drugs (also known as biopharmaceuticals) produced through biological processes are becoming increasingly more common. In addition, mRNA-based gene silencing technologies may have therapeutic applications.
== Biography == Born on 27 September 1958 in the Indian state of Maharashtra, K. V. Subba Rao graduated in science from the University of Pune and before starting his career by joining Malti-Chem Research Centre, Baroda, he secured his master's degree also from the same university in 1979. Subsequently, he did his doctoral studies under Sukhdev at Maharaja Sayajirao University of Baroda and moved to Johns Hopkins University in 1983 for his post-doctoral studies at their Division of Environmental Chemistry where he worked with Miles R. Chedekel. After working for two years there, he joined the laboratory of Fred C. Fox at the University of California and worked there for three more years. Returning to India in 1988, he joined the International Centre for Genetic Engineering and Biotechnology where he held different positions as that of a research scientist (1988–91) and research assistant (1991–94) and was the Group Leader of the Immunology Group (1994-2015).
Sources: en.wikipedia.org
Liquid chromatography-tandem mass spectrometry is a common approach. It can detect the parent compound and its metabolites in biological matrices.
Research samples are typically kept frozen, desiccated, and protected from light. Stock solutions are often aliquoted to reduce freeze-thaw cycles.
High-performance liquid chromatography and nuclear magnetic resonance are standard for purity and identity. Mass spectrometry confirms molecular weight.
Liquid chromatography–mass spectrometry is common for identity and purity checks. High-performance liquid chromatography with ultraviolet detection can also be used. Both methods require a suitable reference standard.